Clinical trial · Observational
Evaluating Serum Sestrin in Leiomyoma Patients
Evaluation of Serum Sestrin Levels in Patients With Leiomyoma
NCT04819633CI-TRIAL-00053996completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Leiomyomas are the most common benign neoplasms of women's reproductive system affecting 20-30% of women within the reproductive ages. Sestrins are serum proteins which are highly expressed under circumstances of DNA damage, hypoxia and oxditive stress and play an important role in autophagia. The aim of this study is to evaluate the relationship of serum sestrin proteins with development of leiomyomas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uterine Leiomyoma | Uterine Corpus Leiomyoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Determination of serum sestrin levels | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Study Group
- description
- 30 patients within the reproductive ages (18-45 years) who were diagnosed with leiomyomas using transvaginal ultrasonography without any additional chronic, systemic or autoimmune disease, are not currently using any medical, hormonal, antiinflammatory treatments are included in this group.
- interventionNames
- Other: Determination of serum sestrin levels
- label
- Control Group
- description
- 30 healthy subjects within the reproductive ages (18-45 years) who visited the outpatient gynecological clinic for routine examination who do not have any additional chronic, systemic or autoimmune disease, who are not currently using any medical, hormonal, antiinflammatory treatments are included in this group.
- interventionNames
- Other: Determination of serum sestrin levels
Primary outcomes (1)
- measure
- Evaluating the role of autophagia in the development of leiomyomas by evaluating the serum sestrin levels.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * 18-45 years of age * patients diagnosed with uterine leiomyomas will be included in the study group * patients without any additional comorbidities * patients without any autoimmune diseases Exclusion Criteria: * patients with systemic diseases * patients with known chronic inflammatory diseases * patients using hormonal and/or medical therapy * pregnant women * lactating women * patients with malignant diseases
References
Publications (0)
Data not yet available
No reference posted for this study.